# A Phase 1 With Extension Cohort, Single Arm, Single Center, Open Label Trial of Belantamab Mafodotin for the Treatment of High-Risk Smoldering Multiple Myeloma

> **NCT05055063** · PHASE1 · RECRUITING · sponsor: **M.D. Anderson Cancer Center** · enrollment: 30 (estimated)

## Conditions studied

- Myeloma

## Interventions

- **DRUG:** Belantamab mafodotin

## Key facts

- **NCT ID:** NCT05055063
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-05-18
- **Primary completion:** 2027-02-02
- **Final completion:** 2027-02-02
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2025-12-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05055063

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05055063, "A Phase 1 With Extension Cohort, Single Arm, Single Center, Open Label Trial of Belantamab Mafodotin for the Treatment of High-Risk Smoldering Multiple Myeloma". Retrieved via AI Analytics 2026-07-11 from https://api.ai-analytics.org/clinical/NCT05055063. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*